Withangulatin A

Withangulatin A is the inhibitor for COX-2. Withangulatin A inhibits MAPK, NF-κB, Akt/mTOR/p70S6K pathway, exhibits antitumor, anti-inflammatory and trypanocidal activities[1][2][3].

Product Specifications

CAS Number

[120824-03-5]

UNSPSC

12352005

Target

Akt; Apoptosis; COX; mTOR; NF-κB; p38 MAPK; Parasite; Reactive Oxygen Species (ROS) ; TGF-beta/Smad

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/withangulatin-a.html

Purity

99.76

Solubility

DMSO : 3 mg/mL (ultrasonic; warming)

Smiles

C[C@]12[C@@]3([C@H](C=CC2=O)O)[C@](C[C@]4([H])[C@]1([H])CC[C@]5([C@]4([C@H](C=C5[C@@H]([C@@]6([H])CC(C)=C(C(O6)=O)C)C)OC(C)=O)O)C)([H])O3

Molecular Formula

C30H38O8

Molecular Weight

526.62

References & Citations

[1] Lijuan Sun, et al. Anti-inflammatory function of Withangulatin A by targeted inhibiting COX-2 expression via MAPK and NF-kappaB pathways. J Cell Biochem. 2010 Feb 15;109 (3) :532-41.|[2]Liu Q, et al., Withagulatin A inhibits hepatic stellate cell viability and procollagen I production through Akt and Smad signaling pathways. Acta Pharmacol Sin. 2010 Aug;31 (8) :944-52. |[3]Chen C, et al., Identification of peroxiredoxin 6 as a direct target of withangulatin A by quantitative chemical proteomics in non-small cell lung cancer. Redox Biol. 2021 Oct;46:102130.